PTP-1B is an essential positive regulator of platelet integrin signaling

Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
The Journal of Cell Biology (Impact Factor: 9.69). 09/2005; 170(5):837-45. DOI: 10.1083/jcb.200503125
Source: PubMed

ABSTRACT Outside-in integrin alphaIIbbeta3 signaling is required for normal platelet thrombus formation and is triggered by c-Src activation through an unknown mechanism. In this study, we demonstrate an essential role for protein-tyrosine phosphatase (PTP)-1B in this process. In resting platelets, c-Src forms a complex with alphaIIbbeta3 and Csk, which phosphorylates c-Src tyrosine 529 to maintain c-Src autoinhibition. Fibrinogen binding to alphaIIbbeta3 triggers PTP-1B recruitment to the alphaIIbbeta3-c-Src-Csk complex in a manner that is dependent on c-Src and specific tyrosine (tyrosine 152 and 153) and proline (proline 309 and 310) residues in PTP-1B. Studies of PTP-1B-deficient mouse platelets indicate that PTP-1B is required for fibrinogen-dependent Csk dissociation from alphaIIbbeta3, dephosphorylation of c-Src tyrosine 529, and c-Src activation. Furthermore, PTP-1B-deficient platelets are defective in outside-in alphaIIbbeta3 signaling in vitro as manifested by poor spreading on fibrinogen and decreased clot retraction, and they exhibit ineffective Ca2+ signaling and thrombus formation in vivo. Thus, PTP-1B is an essential positive regulator of the initiation of outside-in alphaIIbbeta3 signaling in platelets.


Available from: Barry Moran, Jun 04, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rationale: Besides their essential role in hemostasis, platelets also have functions in inflammation. In platelets, junctional adhesion molecule (JAM)-A was previously identified as an inhibitor of integrin αIIbβ3-mediated outside-in signaling and its genetic knockdown resulted in hyperreactivity. Objective: This gain-of-function was specifically exploited to investigate the role of platelet hyperreactivity in plaque development. Methods and Results:: JAM-A-deficient platelets showed increased aggregation and c-Src activation. Upon αIIbβ3 ligation, JAM-A was shown to be dephosphorylated, which could be prevented by PTPN1 inhibition. Mice with or without platelet-specific (tr)JAM-A-deficiency in an apolipoprotein e (apoe(-/-)) background were fed a high-fat diet. After up to 12 weeks of diet, trJAM-A(-/-) apoe(-/-) mice showed increased aortic plaque formation compared with trJAM-A(+/+) apoe(-/-) controls and these differences were most evident at early time points. At 2 weeks, the plaques of the trJAM-A(-/-) apoe(-/-) animals revealed increased macrophage-, T cell- and smooth muscle cell content. Interestingly, plasma levels of chemokines CCL5 and CXCL4 were increased in the trJAM-A(-/-) apoe(-/-) mice and JAM-A-deficient platelets showed increased binding to monocytes and neutrophils. Whole-blood perfusion experiments and intravital microscopy revealed increased recruitment of platelets and monocytes to the inflamed endothelium in blood of trJAM-A(-/-) apoe(-/-) mice. Notably, these pro-inflammatory effects of JAM-A-deficient platelets could be abolished by inhibition of αIIbβ3 signaling in vitro. Conclusions: Deletion of JAM-A causes a gain-of-function in platelets, with lower activation thresholds and increased inflammatory activities. This leads to an increase of plaque formation, particularly in early stages of the disease.
    Circulation Research 12/2014; 116(4). DOI:10.1161/CIRCRESAHA.116.304035 · 11.09 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Src family kinases (SFKs) play a central role in mediating the rapid response of platelets to vascular injury. They transmit activation signals from a diverse repertoire of platelet surface receptors, including the integrin αIIbβ3, the ITAM-containing collagen receptor complex GPVI-FcR γ-chain, and the VWF receptor complex GPIb-IX-V, that are essential for thrombus growth and stability. Ligand-mediated clustering of these receptors triggers an increase in SFK activity and tyrosine phosphorylation of downstream enzymes, adaptors and cytoskeletal proteins that collectively propagate the signal and coordinate platelet activation. A growing body of evidence has established that SFKs also contribute to Gq- and Gi-coupled receptor signaling that synergizes with primary activation signals to maximally activate platelets and render them prothrombotic. Interestingly, SFKs concomitantly activate inhibitory pathways that limit platelet activation and thrombus size. In this review, we discuss past discoveries that laid the foundation for this fundamental area of platelet signal transduction, recent progress in our understanding of the distinct and overlapping functions of SFKs in platelets, and new avenues of research into mechanisms of SFK regulation. We also highlight the thrombotic and haemostatic consequences of targeting platelet SFKs.
    Blood 08/2014; 124(13). DOI:10.1182/blood-2014-01-453134 · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The coagulation process is activated by tight control mechanisms, in which platelets play prominent and unique roles. In thrombosis and hemostasis, activated platelets regulate the coagulation system in various ways: by exposing a phosphatidylserine surface for thrombin formation, by supporting fibrin formation, and by regulating the retraction of a fibrin clot. In this review we discuss the involvement of platelet receptors, other membrane proteins, downstream signaling proteins, cytoskeleton-linked proteins and plasma proteins in these procoagulant functions. Studies with both genetically modified mice and pharmacological inhibitors indicate that, for collagen-adhered platelets, in part common signaling pathways lead to phosphatidylserine exposure, generation of thrombin and fibrin, and retraction of the fibrin clot. However, prolonged Ca(2+) elevation leads to thrombin generation, whereas integrin-dependent signaling stimulates fibrin clot retraction. Contact-dependent signaling pathways, triggered by homotypic platelet-platelet interactions, act in particular via the integrin route. © 2014 Elsevier Ltd. All rights reserved.
    Thrombosis Research 05/2014; 133 Suppl 2:S139-48. DOI:10.1016/S0049-3848(14)50024-2 · 2.43 Impact Factor